Published in J Infect Dis on July 16, 2014
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection | NCT04343755
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure | NCT04353206
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia | NCT04374565
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia | NCT04381858
Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD | NCT04411602
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection | NCT04456413
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma | NCT04468009
Expanded Access to Convalescent Plasma for Treatment of COVID-19 | NCT04472572
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients | NCT04521309
Convalescent Plasma as Adjunct Therapy for COVID-19 (PlaSenTer) | NCT04873414
Middle East respiratory syndrome. Lancet (2015) 3.10
Novel citation-based search method for scientific literature: application to meta-analyses. BMC Med Res Methodol (2015) 1.78
Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev (2015) 1.64
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome. Infect Chemother (2015) 0.97
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus (2015) 0.96
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis (2016) 0.94
The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. Clin Infect Dis (2015) 0.92
Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov (2016) 0.91
Middle East Respiratory Syndrome. N Engl J Med (2017) 0.91
Respiratory Infections in the U.S. Military: Recent Experience and Control. Clin Microbiol Rev (2015) 0.90
Ebola virus disease: the 'Black Swan' in West Africa. Trop Doct (2014) 0.89
Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol (2015) 0.85
A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat Med (2016) 0.82
INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. J Infect Dis (2015) 0.82
Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. Influenza Other Respir Viruses (2014) 0.82
Ebola raises profile of blood-based therapy. Nature (2015) 0.81
Use of Plasma Therapy for Severe Fever with Thrombocytopenia Syndrome Encephalopathy. Emerg Infect Dis (2016) 0.81
Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak. Clin Trials (2016) 0.79
Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu Rev Med (2016) 0.77
Critically ill patients with Middle East respiratory syndrome coronavirus infection. Crit Care (2016) 0.77
Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy. Immunotherapy (2015) 0.76
Middle East respiratory syndrome vaccines. Int J Infect Dis (2016) 0.76
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis (2017) 0.76
Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus (2015) 0.75
Treatment strategies for Middle East respiratory syndrome coronavirus. J Virus Erad (2016) 0.75
Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. J Thorac Dis (2016) 0.75
Swift antibodies to counter emerging viruses. Proc Natl Acad Sci U S A (2015) 0.75
Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome. Ann Lab Med (2016) 0.75
Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection. Sci Rep (2016) 0.75
A Narrative Review of Influenza: A Seasonal and Pandemic Disease. Iran J Med Sci (2017) 0.75
Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. Curr Ther Res Clin Exp (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med (2006) 5.28
Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest (2013) 4.16
State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLoS Curr (2013) 3.41
Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J (2003) 3.01
Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med (2007) 2.53
Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One (2008) 2.28
SARS: systematic review of treatment effects. PLoS Med (2006) 1.74
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis (2011) 1.68
Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. Crit Care Med (2013) 1.51
Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. World J Gastroenterol (2003) 1.31
Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J (2006) 1.31
The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother (2008) 1.25
Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis (2005) 1.23
Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother (2005) 1.03
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One (2011) 1.00
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect (2004) 0.93
Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion (2010) 0.90
[Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area]. Zhonghua Yi Xue Za Zhi (2003) 0.89
Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis (2005) 0.87
Hong Kong's experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1). Hong Kong Med J (2010) 0.84
Severe acute respiratory syndrome (SARS). Transfus Apher Sci (2003) 0.82
[Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula]. Zhonghua Jie He He Hu Xi Za Zhi (2009) 0.82
Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine (2013) 2.69
Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis (2012) 2.67
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis (2010) 2.67
Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults. Thorax (2011) 1.91
Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J (2012) 1.44
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax (2012) 1.40
Bacterial pneumonia and pandemic influenza planning. Emerg Infect Dis (2008) 1.30
Influenza vaccination coverage rates in the UK: a comparison of two monitoring methods during the 2002-2003 and 2003-2004 seasons. Public Health (2006) 1.20
Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis (2013) 1.12
A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period. PLoS One (2012) 1.11
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One (2011) 1.00
Public understanding of pandemic influenza, United Kingdom. Emerg Infect Dis (2006) 0.99
Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. Emerg Infect Dis (2011) 0.99
Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009-2010. Emerg Infect Dis (2011) 0.98
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis (2012) 0.95
Survival of influenza A(H1N1) on materials found in households: implications for infection control. PLoS One (2011) 0.95
Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One (2011) 0.91
Effectiveness of common household cleaning agents in reducing the viability of human influenza A/H1N1. PLoS One (2010) 0.89
Vaccination of health care workers to protect patients at increased risk for acute respiratory disease. Emerg Infect Dis (2012) 0.87
Influenza aerosols in UK hospitals during the H1N1 (2009) pandemic--the risk of aerosol generation during medical procedures. PLoS One (2013) 0.87
The comparative clinical course of pregnant and non-pregnant women hospitalised with influenza A(H1N1)pdm09 infection. PLoS One (2012) 0.87
Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. PLoS One (2012) 0.87
Oseltamivir resistance in influenza A (H5N1) infection. N Engl J Med (2006) 0.86
Developing pandemic preparedness in Europe in the 21st century: experience, evolution and next steps. Bull World Health Organ (2012) 0.84
Minimum dataset for confirmed human cases of influenza H5N1. Lancet (2008) 0.82
Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respir Viruses (2013) 0.81
Adverse medical events in British service personnel following anthrax vaccination. Vaccine (2003) 0.81
Vaccination of healthcare workers to protect patients at increased risk of acute respiratory disease: summary of a systematic review. Influenza Other Respir Viruses (2013) 0.79
Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic. Influenza Other Respir Viruses (2013) 0.78
An evaluation of community assessment tools (CATs) in predicting use of clinical interventions and severe outcomes during the A(H1N1)pdm09 pandemic. PLoS One (2013) 0.78
Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic. J Clin Virol (2010) 0.77
Healthcare workers' willingness to work during an influenza pandemic: a systematic review and meta-analysis. Influenza Other Respir Viruses (2015) 0.75
Preparing for a potential A(H7N9) pandemic: lessons from the deployment of A(H1N1) pandemic vaccines. Expert Rev Vaccines (2013) 0.75
Responding to bird influenza: past, present and future. Travel Med Infect Dis (2008) 0.75
Evaluation of inter-pandemic influenza vaccine effectiveness during eight consecutive winter seasons in England and Wales in patients with cardiovascular risk factors. J Infect Public Health (2010) 0.75